How big is IRIDEX Corp.?

As of Jun 18, IRIDEX Corp. has a market capitalization of 16.35 million and reported net sales of 48.81 million with a net profit of -7.13 million over the latest four quarters. Shareholder's funds are 2.10 million, and total assets amount to 29.14 million.

As of Jun 18, IRIDEX Corp. has a market capitalization of 16.35 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 48.81 million, while the sum of net profit for the same period is -7.13 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 2.10 million, and total assets amount to 29.14 million.

What does IRIDEX Corp. do?

IRIDEX Corporation develops therapeutic laser consoles and devices for treating eye diseases, operating in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $12 million and a market cap of $16.35 million.

Overview: <BR>IRIDEX Corporation is a provider of therapeutic-based laser consoles, delivery devices, and consumable instrumentation used to treat sight-threatening eye diseases in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 12 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 16.35 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 3.52 <BR>Return on Equity: -713.20% <BR>Price to Book: 16.35<BR><BR>Contact Details: <BR>Address: 1212 Terra Bella Ave, MOUNTAIN VIEW CA: 94043-1824 <BR>Tel: ['1 650 9404700', '1 415 9375404'] <BR>Fax: 1 650 9404710 <BR>Website: http://www.iridex.com/

Should I buy, sell or hold IRIDEX Corp.?

Who are in the management team of IRIDEX Corp.?

As of March 2022, the management team of IRIDEX Corp. includes Mr. Robert Gunst (Independent Chairman), Mr. David Bruce (President and CEO), and several Independent Directors: Ms. Doris Engibous, Dr. Robert Grove, Mr. Kenneth Ludlum, and Mr. Scott Shuda. This team provides governance and strategic direction for the company.

As of March 2022, the management team of IRIDEX Corp. includes the following individuals:<BR><BR>- Mr. Robert Gunst, who serves as the Independent Chairman of the Board.<BR>- Mr. David Bruce, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Doris Engibous, who is an Independent Director.<BR>- Dr. Robert Grove, who is also an Independent Director.<BR>- Mr. Kenneth Ludlum, serving as an Independent Director.<BR>- Mr. Scott Shuda, who is an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is IRIDEX Corp. overvalued or undervalued?

As of November 3, 2016, IRIDEX Corp. is considered overvalued and risky due to poor financial metrics, including a Price to Book Value of 16.34 and negative EV to EBIT and EV to EBITDA ratios, which indicate significant profitability challenges compared to its peers.

As of 3 November 2016, the valuation grade for IRIDEX Corp. moved from expensive to risky, indicating a deterioration in its valuation outlook. The company appears to be overvalued based on its current financial metrics. Key ratios include a Price to Book Value of 16.34, an EV to EBIT of -3.81, and an EV to EBITDA of -5.21, all of which suggest significant challenges in profitability and valuation.<BR><BR>In comparison to its peers, IRIDEX Corp. has a notably negative EV to EBITDA ratio of -10.2048, while Kewaunee Scientific Corp. stands out with a more favorable P/E of 13.9568. Other risky peers like iCAD, Inc. and Sensus Healthcare, Inc. also reflect poor valuation metrics, further highlighting IRIDEX's struggles within its industry. Although specific return data is not available, the lack of positive performance against the S&P 500 reinforces the notion of the company's overvaluation amidst its financial difficulties.

Is IRIDEX Corp. technically bullish or bearish?

As of July 10, 2025, IRIDEX Corp. has a mildly bearish trend, influenced by daily moving averages and monthly indicators, despite some bullish signals in weekly MACD and KST.

As of 10 July 2025, the technical trend for IRIDEX Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly MACD and KST show bullish signals. However, the monthly indicators for Bollinger Bands and KST are bearish, contributing to the overall mildly bearish outlook. The RSI shows no signals in both weekly and monthly time frames. There is no available return data to compare the company's performance against the S&P 500.